We are live on ! Find out more
KL

KCK Ltd Portfolio holdings

AUM $15.1M
1-Year Est. Return 30.14%
This Fund
S&P 500
This Quarter Est. Return
-27.25%
1 Year Est. Return
+30.14%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$51.6M
AUM Growth
-$19.6M
Cap. Flow
-$284K
Cap. Flow %
-0.55%
Top 10 Hldgs %
100%
Holding
4
New
Increased
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
IMUX icon
Immunic
IMUX
+$242K
2
RNTX
Rein Therapeutics
RNTX
+$42.2K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SGHT icon
1
Sight Sciences
SGHT
$386M
$30.4M 58.92%
4,776,232
NPCE icon
2
Neuropace
NPCE
$474M
$21.1M 40.88%
5,621,111
RNTX
3
Rein Therapeutics
RNTX
$67.4M
$101K 0.2%
22,341
-10,000
-31% -$42.2K
IMUX icon
4
Immunic
IMUX
$198M
-6,970
Closed -$242K

Similar funds

KCK Ltd's Q3 2022 Portfolio in Review

As of Q3 2022, KCK Ltd held 4 positions worth $51.6M, down 28% from $71.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

KCK Ltd's Q3 2022 filing shows 1 reduced and 1 closed positions. The largest sale was Immunic, an estimated $242K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • KCK Ltd's biggest Q3 2022 reduction was Rein Therapeutics, cutting an estimated $42.2K.
  • KCK Ltd fully exited Immunic in Q3 2022, selling an estimated $242K.
  • KCK Ltd's ten largest holdings make up 100% of its $51.6M portfolio in Q3 2022.
  • KCK Ltd opened 0 new positions and closed 1 in Q3 2022.
  • KCK Ltd's portfolio value fell 28% quarter-over-quarter to $51.6M.

Based on KCK Ltd's 13F filing for Q3 2022, filed 31 Oct 2022.